Natera, Inc.

    Jurisdiction
    United States
    ISIN
    US6323071042 (NTRA)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Read full profile

    Fundamentals

    Net revenue
    €1.68B
    Gross margin
    62.9%
    EBIT
    -€250.45M
    EBIT margin
    -14.9%
    Net income
    -€216.00M
    Net margin
    -12.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.06B +23.1% -€118.57M -45.1%
    €2.42B +17.3% €49.30M -141.6%
    €2.74B +13.0% €102.64M +108.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Chapman Steven Leonard CEO AND PRESIDENT -5.1K $166.53 -$845.81K
    Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS -3K $166.62 -$499.86K
    Chapman Rowan E N/A -2.8K $166.99 -$459.22K
    Fesko John PRESIDENT, CHIEF BUS. OFFICER -678 $155.46 -$105.40K
    Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS -875 $155.46 -$136.03K

    Congress transactions

    Name Transaction date Value
    Josh Gottheimer September 5, 2025 $1.00K–$15.00K
    Josh Gottheimer August 11, 2025 $1.00K–$15.00K
    Josh Gottheimer December 5, 2024 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    Stanley Druckenmiller 3.4M $481.12M -165K Sell
    Cathie Wood 943K $133.36M +55K Buy
    Nancy Zevenbergen 406K $68.59M -24K Sell

    Earnings Calls

    Add to watchlist

    Notifications